SlideShare una empresa de Scribd logo
1 de 47
Descargar para leer sin conexión
‫بسم ا‬
‫الرحمن الرحيم‬
‫قالوا سبحانك ل علم”‬

‫قالوا سبحانك ل علم”‬
‫لنا إل ما علمتنا‬
‫إنك أنت العليم‬
‫“ الحكيم‬
‫صدق ا العظيم‬
‫سورة البقرة ايه 23‬
By
Dr/ Ayman Al-malt
Assistant Lecturer Of Neurology
Faculty of medicine
.Tanta university

10/4/2013
Agenda
Definitions
� Seizure: the clinical manifestation of an
abnormal,
excessive
excitation
and
synchronization of a population of cortical
neurons.
� Epilepsy: recurrent seizures (two or more)
which are not provoked by systemic or acute
neurologic insults.
Epidemiology of Seizures and Epilepsy
� Seizures
• Incidence: 80/100,000 per year
• Cumulative lifetime incidence : 9% (1/3
febrile convulsions)
• � Epilepsy
• Incidence: 45/100,000 per year
• Prevalence: 0.5-1%
• Cumulative lifetime incidence: 3%
Ref.epilepsy final
Ref.epilepsy final
N.B
•At least one of the new AEDs must be used
before considering intractability.
•For the well known epileptic syndromes
with poor prognosis, intractability must be
considered earlier than 2 years.
Refractory Status Epilepticus
defined as:
seizures not responding to 1st line (benzodiazapines)
Or / and
2nd line ( phenytoin/ valproates/ phenobarbitone)
agents.
occurs in ~ 20% patients in status epilepticus.
mortality rate > 20%
How Serious Is The Problem?
-70% of epileptic pts. have a good prognosis.
-30-40 % may develop refractory epilepsy.
-70% pt retain their intractability versus remission.

-Refractory epileptic pts. are more prone to:
*Neurological and Psychosocial retardation.
*Risk of injury(seizure related).
*High mortality: 1.37 per 100 person-years.
Sudden unexplained death in epilepsy patients (SUDEP) is 40 times
more likely among patients who continue to have seizures than in

those who are seizure free.
2- Predictors For Refractory
Epilepsy
1- Early age of onset.
2- Febrile and neonatal convulsions.
3- History Natal Disorders.
4- Mental subnormality.
5- Organic brain damage.
6- Seizure type, frequency, and number.
7- poor initial response to AED.
8. Status epilepticus
9. Long duration of epilepsy on diagnosis.
10. Abnormal EEG, Abnormal CT.
11. Poor psychological andor socio-economic
background
12. Family history of epilepsy
13. genetic prediction (gene polymorphism )
14. localization of the epileptogenic zone
3- Classification of Intractable
Epilepsy
*Medically intractable epilepsy:
.Pseudo intractable. 1
.True intractable. 2
:Medically and surgically intractable*
.Candidates unfit for surgery. 3
.Candidates with failed surgery. 4
(Aicardi, J.1988)
Intractable Epilepsy
Drug resistance may be present→
►
De novo
►
Develop later (MTS):
(Early age of onset, associated Glial proliferation,
dendritic sprouting , synaptic reorginization)

►

Wax-and-wane pattern
4- Common Errors
In Diagnosis and Treatment of
Epilepsy (pseudo refractory)
Ref.epilepsy final
Diagnostic errors
. Misdiagnosis of non-epileptic seizures.
. Misclassification of epileptic seizures.
. Unrecognized progressive brain disease.
.Failure to uncover precipitating factors.
Misdiagnosis is common; 26 percent of individuals
thought to have DRE were incorrectly diagnosed most
often as a result of incomplete historytaking and/or EEG misinterpretation
Ref.epilepsy final
Treatment errors
. Improper choice of drug.
. Inadequate drug dose.
. Inappropriate combination of drugs.
. Drug interaction.
Ref.epilepsy final
Epilepsy co-morbidities- 5
•
•
•
•

Psychosocial/psychiatric: anxiety,depression
Sleep disorders
Migraine
Cognitive Disorders

NB: Better management of epilepsy comorbidities and QOL improvement → better
seizure control and decrease drug resistance
Mechanisms (hypothesis) of- 6
drug resistance in epilepsy
• Two main hypothesis→
IMulti drug-efflux transporters
hypothesis.
II- Drug – target hypothesis.
(Wolfgang L, 2005)

→
(I)The multi-drug transporter hypothesis:
•
•
•
•
•
•
•
•

Transporters e.g. P-gp, MRP1,….
Interfere with pharmacological behavior of most drugs.
Mainly P-gp is involved in multi-drug resistance.
Expressed by tissues with excretory function & bloodbrain barrier,blood-testis barrier, placenta.
Over expressed in pts. with refractory epilepsy.
Is this over expression intrinsic or acquired or both ??
Most of the known AED are substrate for these
transporters.
Functional polymorphism of these transporters may
occur and play another role in pharmakoresistance.
:II) The Drug-target Hypothesis(
• Target brain molecules include→
► Voltage dependant-ion channels
► Neurotransmitter receptors
► Transporters or metabolic enzymes
involved in release, uptake & metabolism of
neurotransmitters.
• NB.
over
expression
of
multi-drug
transporters, AED-target alterations →

pharmacoresistance
Drug Target Alterations
• Decreased efficacy of drugs acting via Na
channels.
• Reduced or lost pharmacosensitivity of Na
channels.
• Down regulation of B1,B2 subunits of Na
channels.
• Decreased efficacy of drugs acting via GABA
mediated inhibition
• Change of GABA receptor subunits (alpha 1,
alpha and delta) expression.
7- Therapeutic strategy for management
of intractable epilepsy
 The following measures should be considered in
succession.
1.

Increase the dose of the 1st line antiepileptic drug has
been chosen for the patient, up to the maximum
clinically tolerated dose N.B* we have to treat the
patient not the serum level, On failure→

2.

Change for another drug of the first line drugs, and
also increase its dose gradually up to the maximum
tolerated dose, on failure →

3.

Permanent addition of a second drug, on failure →
4.

At that point we have to do the following:
A. Re-evaluate the patient even with previous normal
investigations.
B. Look for hidden causes and precipitating factors.
C. Psychological assessment
support are needed more here.

and

psychosocial

D. Some questions should be asked now as:
- Can too much of one drug or too many drugs
may not only produce side effects, but also increase
seizures frequency?
- Can certain drug precipitate certain seizure
5. Return to single drug therapy with the best clinically
tolerated of the previously used antiepileptic drugs
(avoid sedative and hypnotic drugs).
6. Addition of one of the new antiepileptic drugs can be
considered

now

as

add

monotherapy, on failure→

on

therapy

or

as
7. We have to consider the following,
7.1-Alternative non antiepileptic drug therapy as add
on therapy under strict clinical selective criteria
such as:
a.Vagal nerve stimulation.
b.ketogenic diet.
c.Hormonal therapy.
d.Calcium antagonists.
e.Intravenous immunoglobulins.
7.2-Epileptic surgery.
Treatment Algorithm For Medical Management of Epilepsy
Months of
treatment

Patients with newly diagnosed, previously
untreated epilepsy

0

Monotherapy
(drug 1)

4

Success

Failure

Consider withdrawal after2- 5
years of complete seizure control

Alternative monotherapy
(drug 2)

Success

Failure

Consider withdrawal after 5 years
of complete seizure control

Polytherapy
(drug 1 and 2)

Success

Failure

Consider withdrawal after 5 years
(with patient considerations)

Substitution and transfer to
monotherapy with drug 3

Success

Failure

Consider withdrawal after 5 years
(with patient considerations)

Presurgical evaluation?
Diagnostic re-evaluation

8

12

16
(Gram L & Schmidit D. 2000)
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Ref.epilepsy final
Future challenges- 8
• To develop inhibitors for these transporters
e.g verapamil → inhibitor of P-gp.
• To design effective drugs that are not
substrates for these MDR protein.
• Development of new strategies to by-pass the
effect of these drug transporters.
Ref.epilepsy final
Ref.epilepsy final
Score for Assessment of Treatment Failure (D Schmidt,1986)
Index of intractability

Seizures persist despite treatment with

0

-A drug other than a 1st line drug regardless of daily
dose.

1

-1st line drug below the recommended daily dose.

2

-1st line drug within the recommended daily dose.

3

-1st line drug with therapeutic range of plasma
concentration.

4

-1st line drug with maximum tolerable dose.

5

-More than one 1st line drug with maximum tolerable
dose.

6

-More than one 1st line drug with maximum tolerable
dose and 2nd line drugs.
Ref.epilepsy final

Más contenido relacionado

La actualidad más candente

Responsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable EpilepsyResponsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable EpilepsyAllina Health
 
Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy  Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy Ersifa Fatimah
 
Recent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of EpilepsyRecent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of EpilepsyDr Surendra Khosya
 
Anti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsyAnti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsyPramod Krishnan
 
Anestesia para cirugía de epilepsia
Anestesia para cirugía de epilepsiaAnestesia para cirugía de epilepsia
Anestesia para cirugía de epilepsiaSocundianeste
 
Management of seizures
Management of seizuresManagement of seizures
Management of seizuresPraveen Nagula
 
Navigating anti epileptic medications in difficult to treat epilepsies
Navigating anti epileptic medications in difficult to treat epilepsiesNavigating anti epileptic medications in difficult to treat epilepsies
Navigating anti epileptic medications in difficult to treat epilepsiesPramod Krishnan
 
Withdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsWithdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsPramod Krishnan
 
Enoxaparin induced local hypersensitivity reactions a rare case report
Enoxaparin induced local hypersensitivity reactions  a rare case reportEnoxaparin induced local hypersensitivity reactions  a rare case report
Enoxaparin induced local hypersensitivity reactions a rare case reportGangula Amareswara Reddy
 
Recent Advances in migraine
Recent Advances in migraine Recent Advances in migraine
Recent Advances in migraine DR ANUP PETARE
 
Status epilepticus
Status epilepticusStatus epilepticus
Status epilepticusAamir Khan
 
Epilepsy care: Tranisition from paediatric to adult
Epilepsy care: Tranisition from paediatric to adultEpilepsy care: Tranisition from paediatric to adult
Epilepsy care: Tranisition from paediatric to adultPramod Krishnan
 
Mg mangement guidelines
Mg mangement guidelinesMg mangement guidelines
Mg mangement guidelinesNeurologyKota
 
MG comparison, Ocular vs General
MG comparison, Ocular vs GeneralMG comparison, Ocular vs General
MG comparison, Ocular vs GeneralErsifa Fatimah
 
Zonisamide in parkinsons disease
Zonisamide in parkinsons diseaseZonisamide in parkinsons disease
Zonisamide in parkinsons diseasePramod Krishnan
 
Current Epilepsy Treatment Options
Current Epilepsy Treatment OptionsCurrent Epilepsy Treatment Options
Current Epilepsy Treatment OptionsEFEPA
 

La actualidad más candente (20)

Responsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable EpilepsyResponsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable Epilepsy
 
Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy  Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy
 
Recent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of EpilepsyRecent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of Epilepsy
 
Anti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsyAnti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsy
 
Anestesia para cirugía de epilepsia
Anestesia para cirugía de epilepsiaAnestesia para cirugía de epilepsia
Anestesia para cirugía de epilepsia
 
Refractory epilepsy
Refractory epilepsy Refractory epilepsy
Refractory epilepsy
 
Prof mizanur rahman choosing antiseizure drugs
Prof mizanur rahman choosing antiseizure drugsProf mizanur rahman choosing antiseizure drugs
Prof mizanur rahman choosing antiseizure drugs
 
Management of seizures
Management of seizuresManagement of seizures
Management of seizures
 
Navigating anti epileptic medications in difficult to treat epilepsies
Navigating anti epileptic medications in difficult to treat epilepsiesNavigating anti epileptic medications in difficult to treat epilepsies
Navigating anti epileptic medications in difficult to treat epilepsies
 
Withdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsWithdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugs
 
Enoxaparin induced local hypersensitivity reactions a rare case report
Enoxaparin induced local hypersensitivity reactions  a rare case reportEnoxaparin induced local hypersensitivity reactions  a rare case report
Enoxaparin induced local hypersensitivity reactions a rare case report
 
Recent Advances in migraine
Recent Advances in migraine Recent Advances in migraine
Recent Advances in migraine
 
Status epilepticus
Status epilepticusStatus epilepticus
Status epilepticus
 
Epilepsy care: Tranisition from paediatric to adult
Epilepsy care: Tranisition from paediatric to adultEpilepsy care: Tranisition from paediatric to adult
Epilepsy care: Tranisition from paediatric to adult
 
NMDA POSTER
NMDA POSTERNMDA POSTER
NMDA POSTER
 
Mg mangement guidelines
Mg mangement guidelinesMg mangement guidelines
Mg mangement guidelines
 
Migraine
MigraineMigraine
Migraine
 
MG comparison, Ocular vs General
MG comparison, Ocular vs GeneralMG comparison, Ocular vs General
MG comparison, Ocular vs General
 
Zonisamide in parkinsons disease
Zonisamide in parkinsons diseaseZonisamide in parkinsons disease
Zonisamide in parkinsons disease
 
Current Epilepsy Treatment Options
Current Epilepsy Treatment OptionsCurrent Epilepsy Treatment Options
Current Epilepsy Treatment Options
 

Destacado

New microsoft office power point presentation
New microsoft office power point presentationNew microsoft office power point presentation
New microsoft office power point presentationAyman Al-Malt
 
update of Nystagmus 14 11-2012
update of Nystagmus 14 11-2012 update of Nystagmus 14 11-2012
update of Nystagmus 14 11-2012 Ayman Al-Malt
 
post-stroke involuntary movement
post-stroke involuntary movementpost-stroke involuntary movement
post-stroke involuntary movementAyman Al-Malt
 
Study: The Future of VR, AR and Self-Driving Cars
Study: The Future of VR, AR and Self-Driving CarsStudy: The Future of VR, AR and Self-Driving Cars
Study: The Future of VR, AR and Self-Driving CarsLinkedIn
 

Destacado (7)

New microsoft office power point presentation
New microsoft office power point presentationNew microsoft office power point presentation
New microsoft office power point presentation
 
Genetics of stroke
Genetics of strokeGenetics of stroke
Genetics of stroke
 
update of Nystagmus 14 11-2012
update of Nystagmus 14 11-2012 update of Nystagmus 14 11-2012
update of Nystagmus 14 11-2012
 
post-stroke involuntary movement
post-stroke involuntary movementpost-stroke involuntary movement
post-stroke involuntary movement
 
Moyamoya disease
Moyamoya diseaseMoyamoya disease
Moyamoya disease
 
Dystonia
Dystonia Dystonia
Dystonia
 
Study: The Future of VR, AR and Self-Driving Cars
Study: The Future of VR, AR and Self-Driving CarsStudy: The Future of VR, AR and Self-Driving Cars
Study: The Future of VR, AR and Self-Driving Cars
 

Similar a Ref.epilepsy final

recent seminar topic for m.pharm
recent seminar topic for m.pharmrecent seminar topic for m.pharm
recent seminar topic for m.pharmnilesh1208
 
SEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENT
SEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENTSEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENT
SEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENTKush Bhagat
 
anti NMDA receptor encephalitis - Copy.pptx
 anti NMDA receptor encephalitis - Copy.pptx anti NMDA receptor encephalitis - Copy.pptx
anti NMDA receptor encephalitis - Copy.pptxsumeetsingh837653
 
Alzheimer Disease New.ppt
Alzheimer Disease New.pptAlzheimer Disease New.ppt
Alzheimer Disease New.pptSamerHeraki
 
Management of Refractory, Super refractory SE and.pptx
Management of Refractory, Super refractory SE and.pptxManagement of Refractory, Super refractory SE and.pptx
Management of Refractory, Super refractory SE and.pptxsumeetsingh837653
 
NEW GUIDELINES FOR Status epilepticus
NEW GUIDELINES FOR Status epilepticus NEW GUIDELINES FOR Status epilepticus
NEW GUIDELINES FOR Status epilepticus njdfmudhol
 
Stiripentol and Rufinamide
Stiripentol and RufinamideStiripentol and Rufinamide
Stiripentol and RufinamidePramod Krishnan
 
A Review on the Treatments of Epilepsy
A Review on the Treatments of EpilepsyA Review on the Treatments of Epilepsy
A Review on the Treatments of Epilepsypaperpublications3
 
presurgical evaluation of epilepsy
presurgical evaluation of epilepsypresurgical evaluation of epilepsy
presurgical evaluation of epilepsySrirama Anjaneyulu
 
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...Zahiruddin Othman
 
MANAGEMENT OF SEIZURES AND EPILEPSY9-1.pptx
MANAGEMENT OF SEIZURES AND  EPILEPSY9-1.pptxMANAGEMENT OF SEIZURES AND  EPILEPSY9-1.pptx
MANAGEMENT OF SEIZURES AND EPILEPSY9-1.pptxVyomakesh raju
 
Status epilepticus
Status epilepticusStatus epilepticus
Status epilepticusnancygalaly
 
Approach to patient with convulsion
Approach to patient with convulsionApproach to patient with convulsion
Approach to patient with convulsionAli Abdallah
 

Similar a Ref.epilepsy final (20)

recent seminar topic for m.pharm
recent seminar topic for m.pharmrecent seminar topic for m.pharm
recent seminar topic for m.pharm
 
SEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENT
SEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENTSEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENT
SEIZURE DISORDER MEDICAL AND SURGICAL MANAGEMENT
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
anti NMDA receptor encephalitis - Copy.pptx
 anti NMDA receptor encephalitis - Copy.pptx anti NMDA receptor encephalitis - Copy.pptx
anti NMDA receptor encephalitis - Copy.pptx
 
Alzheimer Disease New.ppt
Alzheimer Disease New.pptAlzheimer Disease New.ppt
Alzheimer Disease New.ppt
 
Management of Refractory, Super refractory SE and.pptx
Management of Refractory, Super refractory SE and.pptxManagement of Refractory, Super refractory SE and.pptx
Management of Refractory, Super refractory SE and.pptx
 
Antipsychotics 07web
Antipsychotics 07webAntipsychotics 07web
Antipsychotics 07web
 
Seizure disorders
Seizure disordersSeizure disorders
Seizure disorders
 
Anti epileptics
Anti epilepticsAnti epileptics
Anti epileptics
 
NEW GUIDELINES FOR Status epilepticus
NEW GUIDELINES FOR Status epilepticus NEW GUIDELINES FOR Status epilepticus
NEW GUIDELINES FOR Status epilepticus
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Stiripentol and Rufinamide
Stiripentol and RufinamideStiripentol and Rufinamide
Stiripentol and Rufinamide
 
A Review on the Treatments of Epilepsy
A Review on the Treatments of EpilepsyA Review on the Treatments of Epilepsy
A Review on the Treatments of Epilepsy
 
presurgical evaluation of epilepsy
presurgical evaluation of epilepsypresurgical evaluation of epilepsy
presurgical evaluation of epilepsy
 
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...
 
Epilepsy treatment
Epilepsy treatmentEpilepsy treatment
Epilepsy treatment
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
MANAGEMENT OF SEIZURES AND EPILEPSY9-1.pptx
MANAGEMENT OF SEIZURES AND  EPILEPSY9-1.pptxMANAGEMENT OF SEIZURES AND  EPILEPSY9-1.pptx
MANAGEMENT OF SEIZURES AND EPILEPSY9-1.pptx
 
Status epilepticus
Status epilepticusStatus epilepticus
Status epilepticus
 
Approach to patient with convulsion
Approach to patient with convulsionApproach to patient with convulsion
Approach to patient with convulsion
 

Último

CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 

Último (20)

CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 

Ref.epilepsy final

  • 1. ‫بسم ا‬ ‫الرحمن الرحيم‬ ‫قالوا سبحانك ل علم”‬ ‫قالوا سبحانك ل علم”‬ ‫لنا إل ما علمتنا‬ ‫إنك أنت العليم‬ ‫“ الحكيم‬ ‫صدق ا العظيم‬ ‫سورة البقرة ايه 23‬
  • 2. By Dr/ Ayman Al-malt Assistant Lecturer Of Neurology Faculty of medicine .Tanta university 10/4/2013
  • 4. Definitions � Seizure: the clinical manifestation of an abnormal, excessive excitation and synchronization of a population of cortical neurons. � Epilepsy: recurrent seizures (two or more) which are not provoked by systemic or acute neurologic insults.
  • 5. Epidemiology of Seizures and Epilepsy � Seizures • Incidence: 80/100,000 per year • Cumulative lifetime incidence : 9% (1/3 febrile convulsions) • � Epilepsy • Incidence: 45/100,000 per year • Prevalence: 0.5-1% • Cumulative lifetime incidence: 3%
  • 8. N.B •At least one of the new AEDs must be used before considering intractability. •For the well known epileptic syndromes with poor prognosis, intractability must be considered earlier than 2 years.
  • 9. Refractory Status Epilepticus defined as: seizures not responding to 1st line (benzodiazapines) Or / and 2nd line ( phenytoin/ valproates/ phenobarbitone) agents. occurs in ~ 20% patients in status epilepticus. mortality rate > 20%
  • 10. How Serious Is The Problem? -70% of epileptic pts. have a good prognosis. -30-40 % may develop refractory epilepsy. -70% pt retain their intractability versus remission. -Refractory epileptic pts. are more prone to: *Neurological and Psychosocial retardation. *Risk of injury(seizure related). *High mortality: 1.37 per 100 person-years. Sudden unexplained death in epilepsy patients (SUDEP) is 40 times more likely among patients who continue to have seizures than in  those who are seizure free.
  • 11. 2- Predictors For Refractory Epilepsy 1- Early age of onset. 2- Febrile and neonatal convulsions. 3- History Natal Disorders. 4- Mental subnormality. 5- Organic brain damage. 6- Seizure type, frequency, and number. 7- poor initial response to AED.
  • 12. 8. Status epilepticus 9. Long duration of epilepsy on diagnosis. 10. Abnormal EEG, Abnormal CT. 11. Poor psychological andor socio-economic background 12. Family history of epilepsy 13. genetic prediction (gene polymorphism ) 14. localization of the epileptogenic zone
  • 13. 3- Classification of Intractable Epilepsy *Medically intractable epilepsy: .Pseudo intractable. 1 .True intractable. 2 :Medically and surgically intractable* .Candidates unfit for surgery. 3 .Candidates with failed surgery. 4 (Aicardi, J.1988)
  • 14. Intractable Epilepsy Drug resistance may be present→ ► De novo ► Develop later (MTS): (Early age of onset, associated Glial proliferation, dendritic sprouting , synaptic reorginization) ► Wax-and-wane pattern
  • 15. 4- Common Errors In Diagnosis and Treatment of Epilepsy (pseudo refractory)
  • 17. Diagnostic errors . Misdiagnosis of non-epileptic seizures. . Misclassification of epileptic seizures. . Unrecognized progressive brain disease. .Failure to uncover precipitating factors. Misdiagnosis is common; 26 percent of individuals thought to have DRE were incorrectly diagnosed most often as a result of incomplete historytaking and/or EEG misinterpretation
  • 19. Treatment errors . Improper choice of drug. . Inadequate drug dose. . Inappropriate combination of drugs. . Drug interaction.
  • 21. Epilepsy co-morbidities- 5 • • • • Psychosocial/psychiatric: anxiety,depression Sleep disorders Migraine Cognitive Disorders NB: Better management of epilepsy comorbidities and QOL improvement → better seizure control and decrease drug resistance
  • 22. Mechanisms (hypothesis) of- 6 drug resistance in epilepsy • Two main hypothesis→ IMulti drug-efflux transporters hypothesis. II- Drug – target hypothesis. (Wolfgang L, 2005) →
  • 23. (I)The multi-drug transporter hypothesis: • • • • • • • • Transporters e.g. P-gp, MRP1,…. Interfere with pharmacological behavior of most drugs. Mainly P-gp is involved in multi-drug resistance. Expressed by tissues with excretory function & bloodbrain barrier,blood-testis barrier, placenta. Over expressed in pts. with refractory epilepsy. Is this over expression intrinsic or acquired or both ?? Most of the known AED are substrate for these transporters. Functional polymorphism of these transporters may occur and play another role in pharmakoresistance.
  • 24. :II) The Drug-target Hypothesis( • Target brain molecules include→ ► Voltage dependant-ion channels ► Neurotransmitter receptors ► Transporters or metabolic enzymes involved in release, uptake & metabolism of neurotransmitters. • NB. over expression of multi-drug transporters, AED-target alterations → pharmacoresistance
  • 25. Drug Target Alterations • Decreased efficacy of drugs acting via Na channels. • Reduced or lost pharmacosensitivity of Na channels. • Down regulation of B1,B2 subunits of Na channels. • Decreased efficacy of drugs acting via GABA mediated inhibition • Change of GABA receptor subunits (alpha 1, alpha and delta) expression.
  • 26. 7- Therapeutic strategy for management of intractable epilepsy  The following measures should be considered in succession. 1. Increase the dose of the 1st line antiepileptic drug has been chosen for the patient, up to the maximum clinically tolerated dose N.B* we have to treat the patient not the serum level, On failure→ 2. Change for another drug of the first line drugs, and also increase its dose gradually up to the maximum tolerated dose, on failure → 3. Permanent addition of a second drug, on failure →
  • 27. 4. At that point we have to do the following: A. Re-evaluate the patient even with previous normal investigations. B. Look for hidden causes and precipitating factors. C. Psychological assessment support are needed more here. and psychosocial D. Some questions should be asked now as: - Can too much of one drug or too many drugs may not only produce side effects, but also increase seizures frequency? - Can certain drug precipitate certain seizure
  • 28. 5. Return to single drug therapy with the best clinically tolerated of the previously used antiepileptic drugs (avoid sedative and hypnotic drugs). 6. Addition of one of the new antiepileptic drugs can be considered now as add monotherapy, on failure→ on therapy or as
  • 29. 7. We have to consider the following, 7.1-Alternative non antiepileptic drug therapy as add on therapy under strict clinical selective criteria such as: a.Vagal nerve stimulation. b.ketogenic diet. c.Hormonal therapy. d.Calcium antagonists. e.Intravenous immunoglobulins. 7.2-Epileptic surgery.
  • 30. Treatment Algorithm For Medical Management of Epilepsy Months of treatment Patients with newly diagnosed, previously untreated epilepsy 0 Monotherapy (drug 1) 4 Success Failure Consider withdrawal after2- 5 years of complete seizure control Alternative monotherapy (drug 2) Success Failure Consider withdrawal after 5 years of complete seizure control Polytherapy (drug 1 and 2) Success Failure Consider withdrawal after 5 years (with patient considerations) Substitution and transfer to monotherapy with drug 3 Success Failure Consider withdrawal after 5 years (with patient considerations) Presurgical evaluation? Diagnostic re-evaluation 8 12 16 (Gram L & Schmidit D. 2000)
  • 43. Future challenges- 8 • To develop inhibitors for these transporters e.g verapamil → inhibitor of P-gp. • To design effective drugs that are not substrates for these MDR protein. • Development of new strategies to by-pass the effect of these drug transporters.
  • 46. Score for Assessment of Treatment Failure (D Schmidt,1986) Index of intractability Seizures persist despite treatment with 0 -A drug other than a 1st line drug regardless of daily dose. 1 -1st line drug below the recommended daily dose. 2 -1st line drug within the recommended daily dose. 3 -1st line drug with therapeutic range of plasma concentration. 4 -1st line drug with maximum tolerable dose. 5 -More than one 1st line drug with maximum tolerable dose. 6 -More than one 1st line drug with maximum tolerable dose and 2nd line drugs.

Notas del editor

  1. Sudep 24 t gp 40 seizure free epilepsy 2-3 t gp Burns fracture head injury